放射線治療の世界市場予測（～2023年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY 23
1.5 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 26
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 27
2.1.2.1 Key data from primary sources 28
2.2 MARKET SIZE ESTIMATION 30
2.2.1 PRODUCT-BASED MARKET ESTIMATION 30
2.2.2 PRIMARY RESEARCH VALIDATION 32
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS 34
2.4.1 LIMITATIONS 34
2.4.2 ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHTS 40
4.1 RADIOTHERAPY MARKET OVERVIEW 40
4.2 EUROPE: EXTERNAL RADIOTHERAPY MARKET, BY TYPE, 2018 41
4.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE 42
4.4 EXTERNAL BEAM RADIOTHERAPY MARKET, BY APPLICATION 43
4.5 REGIONAL ANALYSIS: RADIOTHERAPY MARKET, BY END USER 44
4.6 RADIOTHERAPY MARKET, BY COUNTRY 45
 
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
5.2.1 DRIVERS 47
5.2.1.1 Technological advancements 47
5.2.1.2 Rising prevalence of cancer 48
5.2.1.3 Increasing number of conferences and symposia focusing on spreading awareness about the benefits of radiotherapy 50
5.2.1.4 Growing use of particle therapy for cancer treatment 50
5.2.2 RESTRAINTS 51
5.2.2.1 Lack of adequate healthcare infrastructure 51
5.2.2.2 Shortage of trained personnel 51
5.2.2.3 Affordability and accessibility of treatment 52
5.2.2.4 Complex nature of radiotherapy 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emerging markets 53
5.2.3.2 Growing government and private investments to meet the increasing demand for cancer treatment 54
5.2.3.3 Improving reimbursement scenario 54
5.2.4 CHALLENGES 55
5.2.4.1 Difficulties in visualizing tumors during radiotherapy procedures 55
5.2.4.2 Risk of radiation exposure 55
5.3 INDUSTRY TRENDS 56
5.3.1 GROWING ADOPTION OF PENCIL-BEAM SCANNING 56
5.3.2 GROWING NUMBER OF COLLABORATIONS AND ACQUISITIONS 56
6 RADIOTHERAPY MARKET, BY PRODUCT TYPE 58
6.1 INTRODUCTION 59
6.2 EXTERNAL BEAM RADIOTHERAPY 60
6.2.1 LINEAR ACCELERATORS 61
6.2.1.1 Conventional Linear Accelerators 62
6.2.1.1.1 Lower equipment and maintenance cost will drive the market for conventional LINACs 62
6.2.1.2 Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators 63
6.2.1.2.1 Automation and real-time tracking features have ensured demand for stereotactic advanced LINAC 63
6.2.1.2.2 Gamma Knife 64
6.2.1.2.2.1 The Gamma Knife system is considered a gold standard for brain tumor treatment 64
6.2.1.2.3 CyberKnife 65
6.2.1.2.3.1 CyberKnife offers a precise radiation delivery method with specialized tracking and robotic correction capabilities 65
 
6.2.1.2.4 TomoTherapy 66
6.2.1.2.4.1 360-degree (helical) radiation treatment with TomoTherapy is adding growth opportunities to this segment 66
6.2.2 PARTICLE THERAPY SYSTEMS 67
6.2.2.1 Cyclotrons 68
6.2.2.1.1 Leading players in the particle therapy market mainly manufacture cyclotrons 68
6.2.2.2 Synchrotrons 69
6.2.2.2.1 Increasing investment for the development of synchrotron facilities are contributing to market growth 69
6.2.2.3 Synchrocyclotrons 70
6.2.2.3.1 High space requirements of synchrocyclotrons are limiting its widespread adoption 70
6.2.3 CONVENTIONAL COBALT-60 TELETHERAPY UNITS 71
6.2.3.1 High cost and risk of radiation exposure with cobalt-60 radioisotopes have hindered the growth of this segment 71
6.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 72
6.3.1 SEEDS 74
6.3.1.1 Adverse side-effects associated with seeds limit their adoption 74
6.3.2 APPLICATORS 75
6.3.2.1 Manual applicators pose a high risk of radiation exposure to the patients and staff 75
6.3.3 AFTERLOADERS 76
6.3.3.1 Modern afterloaders offer proper positioning and better control of isotopes inside the patient body 76
6.3.4 ELECTRONIC BRACHYTHERAPY PRODUCTS 77
6.3.4.1 Electronic brachytherapy requires low amount of shielding than alternatives 77
6.4 SYSTEMIC RADIOTHERAPY 78
6.4.1 IOBENGUANE (I-131) 78
6.4.1.1 Increasing incidence of thyroid cancer is driving the growth of this segment 78
6.4.2 SAMARIUM-153 78
6.4.2.1 Samarium-153 has wide applications for bone metastasis 78
6.4.3 RHENIUM-186 79
6.4.3.1 Lack of insurance coverage with the use of Rhenium-186 restricting its growth 79
6.4.4 OTHER SYSTEMIC RADIOTHERAPY PRODUCTS 79
 
7 RADIOTHERAPY MARKET, BY TYPE 80
7.1 INTRODUCTION 81
7.2 EXTERNAL BEAM RADIOTHERAPY 81
7.2.1 IMAGE-GUIDED RADIOTHERAPY 83
7.2.1.1 Image-guided radiotherapy is widely used to the treatment of deep-seated tumors 83
7.2.2 3D CONFORMAL RADIOTHERAPY 84
7.2.2.1 Multiple beams with 3D-CRT allow precise radiation conforming to the tumor size and shape 84
7.2.3 INTENSITY-MODULATED RADIOTHERAPY 85
7.2.3.1 Volumetric Arc Therapy 86
7.2.3.1.1 Advancements in the VMAT technology driving its widespread adoption 86
7.2.3.2 TomoTherapy 87
7.2.3.2.1 Minimal exposure to normal tissues – A major advantage of TomoTherapy 87
7.2.4 STEREOTACTIC THERAPY 88
7.2.4.1 Stereotactic therapy offers a minimally invasive alternative to ablation surgeries 88
7.2.5 PARTICLE THERAPY 89
7.2.5.1 Particle therapy is increasingly being adopted as a primary mode of treatment for various cancer types 89
7.3 INTERNAL BEAM RADIOTHERAPY 91
7.3.1 LOW-DOSE-RATE BRACHYTHERAPY 93
7.3.1.1 Lower risk of radiation exposure to the surrounding tissues with LDR supporting market growth 93
7.3.2 HIGH-DOSE-RATE BRACHYTHERAPY 94
7.3.2.1 Better patient care with HDR is driving its widespread adoption 94
7.3.3 PULSED-DOSE-RATE BRACHYTHERAPY 94
7.3.3.1 Pulsed-dose rate brachytherapy combines the advantages of HDR and LDR brachytherapy 94
7.4 SYSTEMIC RADIOTHERAPY 95
7.4.1 INTRAVENOUS RADIOTHERAPY 95
7.4.1.1 Intravenous route of brachytherapy results in maximum bioavailability 95
7.4.2 ORAL RADIOTHERAPY 96
7.4.2.1 Longer distribution time associated with the oral mode of radiation delivery limiting its demand 96
7.4.3 INSTILLATION RADIOTHERAPY 96
7.4.3.1 Lesser localization with instillation brachytherapy is limiting its widespread adoption 96
 
8 RADIOTHERAPY MARKET, BY APPLICATION 97
8.1 INTRODUCTION 98
8.2 EXTERNAL BEAM RADIATION THERAPY 98
8.2.1 PROSTATE CANCER 100
8.2.1.1 High incidence of prostate cancer will drive the demand for EBRT 100
8.2.2 BREAST CANCER 101
8.2.2.1 Adoption of advanced EBRT systems and increasing research will drive market growth 101
8.2.3 LUNG CANCER 102
8.2.3.1 Radiotherapy can be used as solo or combination therapy for lung cancer 102
8.2.4 HEAD AND NECK CANCER 103
8.2.4.1 Benefits of external radiotherapy will support its use in head and neck cancer treatment 103
8.2.5 COLORECTAL CANCER 104
8.2.5.1 Availability of alternative therapeutic options limits the growth of this segment 104
8.2.6 OTHER CANCERS 105
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 106
8.3.1 PROSTATE CANCER 107
8.3.1.1 Rapidity and precision of brachytherapy in prostate cancer treatment have driven market growth 107
8.3.2 GYNECOLOGICAL CANCER 108
8.3.2.1 Availability of alternatives hinders the adoption of brachytherapy in gynecological cancer treatment 108
8.3.3 BREAST CANCER 109
8.3.3.1 Precision and rapid treatment times are driving the use of brachytherapy in breast cancer applications 109
8.3.4 CERVICAL CANCER 110
8.3.4.1 A combination of brachytherapy and chemotherapy is typically used for cervical cancer treatment 110
8.3.5 PENILE CANCER 111
8.3.5.1 Advantages of brachytherapy in penile cancer treatment have driven its adoption 111
8.3.6 OTHER CANCERS 112
9 RADIOTHERAPY MARKET, BY END USER 114
9.1 INTRODUCTION 115
9.1.1 HOSPITALS 116
9.1.1.1 Increasing number of small-footprint advanced radiotherapy products promoting their adoption in hospitals 116
9.1.2 INDEPENDENT RADIOTHERAPY CENTERS 117
9.1.2.1 Rising consolidation of healthcare networks is challenging the growth of freestanding radiotherapy centers 117
10 RADIOTHERAPY MARKET, BY REGION 119
10.1 INTRODUCTION 120
10.2 NORTH AMERICA 120
10.2.1 US 127
10.2.1.1 Growing government initiatives boosting the adoption of radiotherapy in the US 127
10.2.2 CANADA 129
10.2.2.1 Rising cancer incidence driving the demand for radiotherapy in Canada 129
10.3 EUROPE 132
10.3.1 GERMANY 139
10.3.1.1 Increasing awareness of novel and advanced radiotherapy products a key factor contributing to market growth 139
10.3.2 FRANCE 141
10.3.2.1 Growing government initiatives boosting the adoption of radiotherapy in France 141
10.3.3 UK 143
10.3.3.1 Leading market players focusing on expanding their product offerings in the UK 143
10.3.4 REST OF EUROPE 145
10.4 ASIA PACIFIC 148
10.4.1 CHINA 156
10.4.1.1 Presence of a large number of local manufactures supporting the growth of the radiotherapy market in China 156
10.4.2 JAPAN 158
10.4.2.1 Rising prevalence of cancer is driving the adoption of radiotherapy in Japan 158
10.4.3 INDIA 160
10.4.3.1 Shortage of skilled radiotherapy professionals in India is restraining market growth 160
10.4.4 REST OF ASIA PACIFIC 162
10.5 REST OF THE WORLD 165
11 COMPETITIVE LANDSCAPE 173
11.1 INTRODUCTION 173
11.2 MARKET SHARE ANALYSIS 175
11.3 COMPETITIVE SCENARIO 176
11.3.1 PRODUCT LAUNCHES AND APPROVALS 176
11.3.2 ACQUISITIONS 176
11.3.3 EXPANSIONS 177
11.3.4 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 177
11.4 VENDOR DIVE OVERVIEW 178
11.5 VENDOR INCLUSION CRITERIA 178
 
11.6 VENDOR DIVE 178
11.6.1 VANGUARDS 178
11.6.2 INNOVATORS 179
11.6.3 DYNAMIC PLAYERS 179
11.6.4 EMERGING COMPANIES 179
12 COMPANY PROFILES 182
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 ACCURAY INCORPORATED 182
12.2 C. R. BARD, INC. 185
12.3 ELEKTA 187
12.4 HITACHI, LTD. 192
12.5 IBA (ION BEAM APPLICATIONS SA) 194
12.6 ISORAY MEDICAL, INC. 198
12.7 MEVION MEDICAL SYSTEMS, INC. 200
12.8 OPTIVUS PROTON THERAPY, INC. 202
12.9 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 203
12.10 P-CURE LTD. 204
12.11 PROVISION HEALTHCARE, LLC. 205
12.12 SUMITOMO HEAVY INDUSTRIES, LTD 207
12.13 THERAGENICS CORPORATION 209
12.14 VARIAN MEDICAL SYSTEMS, INC. 210
12.15 VIEWRAY INC. 215

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 218
13.1 DISCUSSION GUIDE 218
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 223
13.3 AVAILABLE CUSTOMIZATIONS 225
13.4 RELATED REPORTS 225
13.5 AUTHOR DETAILS 226